Sitagliptin Results in a Decrease of Truncated Apolipoprotein C1

Nicole E.B. Skinner, Matthew S. Wroblewski, Julie A. Kirihara, Gary L. Nelsestuen, Elizabeth R. Seaquist

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Apolipoprotein C1 (ApoC1) is a component of multiple lipoproteins where it performs a variety of roles in lipid metabolism and transport. ApoC1 exists as both full-length and truncated isoforms. Truncation of ApoC1 has been postulated to result from the action of dipeptidyl peptidase-4 (DPP-4), the target of a new class of diabetes drugs that includes sitagliptin phosphate. In this study, we sought to determine if oral administration of sitagliptin altered the proportion of ApoC1 isoforms circulating in humans. Results indicated a dramatic change in ApoC1 truncation, consistent with a high level of DPP-4 inhibition by sitagliptin. Funding: University of Minnesota, Minneapolis, MN, USA.

Original languageEnglish (US)
Pages (from-to)395-401
Number of pages7
JournalDiabetes Therapy
Volume6
Issue number3
DOIs
StatePublished - Sep 26 2015

Fingerprint

Apolipoprotein C-I
Dipeptidyl Peptidase 4
Protein Isoforms
Lipid Metabolism
Lipoproteins
Oral Administration
Sitagliptin Phosphate
Pharmaceutical Preparations

Keywords

  • Apolipoprotein C1
  • Mass spectrometry
  • Sitagliptin

Cite this

Sitagliptin Results in a Decrease of Truncated Apolipoprotein C1. / Skinner, Nicole E.B.; Wroblewski, Matthew S.; Kirihara, Julie A.; Nelsestuen, Gary L.; Seaquist, Elizabeth R.

In: Diabetes Therapy, Vol. 6, No. 3, 26.09.2015, p. 395-401.

Research output: Contribution to journalArticle

Skinner, Nicole E.B. ; Wroblewski, Matthew S. ; Kirihara, Julie A. ; Nelsestuen, Gary L. ; Seaquist, Elizabeth R. / Sitagliptin Results in a Decrease of Truncated Apolipoprotein C1. In: Diabetes Therapy. 2015 ; Vol. 6, No. 3. pp. 395-401.
@article{770e15cad7e74842af6f5612df54fdeb,
title = "Sitagliptin Results in a Decrease of Truncated Apolipoprotein C1",
abstract = "Apolipoprotein C1 (ApoC1) is a component of multiple lipoproteins where it performs a variety of roles in lipid metabolism and transport. ApoC1 exists as both full-length and truncated isoforms. Truncation of ApoC1 has been postulated to result from the action of dipeptidyl peptidase-4 (DPP-4), the target of a new class of diabetes drugs that includes sitagliptin phosphate. In this study, we sought to determine if oral administration of sitagliptin altered the proportion of ApoC1 isoforms circulating in humans. Results indicated a dramatic change in ApoC1 truncation, consistent with a high level of DPP-4 inhibition by sitagliptin. Funding: University of Minnesota, Minneapolis, MN, USA.",
keywords = "Apolipoprotein C1, Mass spectrometry, Sitagliptin",
author = "Skinner, {Nicole E.B.} and Wroblewski, {Matthew S.} and Kirihara, {Julie A.} and Nelsestuen, {Gary L.} and Seaquist, {Elizabeth R.}",
year = "2015",
month = "9",
day = "26",
doi = "10.1007/s13300-015-0123-1",
language = "English (US)",
volume = "6",
pages = "395--401",
journal = "Diabetes Therapy",
issn = "1869-6953",
publisher = "Springer Publishing Company",
number = "3",

}

TY - JOUR

T1 - Sitagliptin Results in a Decrease of Truncated Apolipoprotein C1

AU - Skinner, Nicole E.B.

AU - Wroblewski, Matthew S.

AU - Kirihara, Julie A.

AU - Nelsestuen, Gary L.

AU - Seaquist, Elizabeth R.

PY - 2015/9/26

Y1 - 2015/9/26

N2 - Apolipoprotein C1 (ApoC1) is a component of multiple lipoproteins where it performs a variety of roles in lipid metabolism and transport. ApoC1 exists as both full-length and truncated isoforms. Truncation of ApoC1 has been postulated to result from the action of dipeptidyl peptidase-4 (DPP-4), the target of a new class of diabetes drugs that includes sitagliptin phosphate. In this study, we sought to determine if oral administration of sitagliptin altered the proportion of ApoC1 isoforms circulating in humans. Results indicated a dramatic change in ApoC1 truncation, consistent with a high level of DPP-4 inhibition by sitagliptin. Funding: University of Minnesota, Minneapolis, MN, USA.

AB - Apolipoprotein C1 (ApoC1) is a component of multiple lipoproteins where it performs a variety of roles in lipid metabolism and transport. ApoC1 exists as both full-length and truncated isoforms. Truncation of ApoC1 has been postulated to result from the action of dipeptidyl peptidase-4 (DPP-4), the target of a new class of diabetes drugs that includes sitagliptin phosphate. In this study, we sought to determine if oral administration of sitagliptin altered the proportion of ApoC1 isoforms circulating in humans. Results indicated a dramatic change in ApoC1 truncation, consistent with a high level of DPP-4 inhibition by sitagliptin. Funding: University of Minnesota, Minneapolis, MN, USA.

KW - Apolipoprotein C1

KW - Mass spectrometry

KW - Sitagliptin

UR - http://www.scopus.com/inward/record.url?scp=84942323622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942323622&partnerID=8YFLogxK

U2 - 10.1007/s13300-015-0123-1

DO - 10.1007/s13300-015-0123-1

M3 - Article

C2 - 26198273

AN - SCOPUS:84942323622

VL - 6

SP - 395

EP - 401

JO - Diabetes Therapy

JF - Diabetes Therapy

SN - 1869-6953

IS - 3

ER -